How do intermediate endpoint markers respond to lycopene in men with prostate cancer or benign prostate hyperplasia?
van Breemen
Richard B
RB
Department of Medicinal Chemistry and Pharmacognosy, University of Illinois College of Pharmacy, Chicago, 60612, USA. Breemen@uic.edu
D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002338:Carotenoids / Q000627:therapeutic use*; D006801:Humans; D000077276:Lycopene; D008297:Male; D010919:Placebos; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood*; D011471:Prostatic Neoplasms / Q000473:pathology*; D015203:Reproducibility of Results
D016588:Anticarcinogenic Agents; D015415:Biomarkers; D010919:Placebos; D002338:Carotenoids; D017430:Prostate-Specific Antigen; D000077276:Lycopene